Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 6, 2012, Pages 432-439

  Roke, Yvette ^a   Buitelaar, Jan K ^b   Boot, Annemieke M ^c   Tenback, Diederik ^a   Van Harten, Peter N ^a,d  

^a Psychiatric Centre GGZ Centraal   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; MELATONIN; PALIPERIDONE; PROLACTIN; PSYCHOSTIMULANT AGENT; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; ASYMPTOMATIC HYPERPROLACTINEMIA; AUTISM; CHILD; CHILD PSYCHIATRY; CONTROLLED STUDY; DISRUPTIVE BEHAVIOR; DRUG BLOOD LEVEL; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHYSICAL EXAMINATION; PROLACTIN BLOOD LEVEL; PUBERTY; QUESTIONNAIRE; RISK ASSESSMENT; SCHOOL CHILD; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GYNECOMASTIA; HUMANS; HYPERPROLACTINEMIA; ISOXAZOLES; LOGISTIC MODELS; MALE; PROLACTIN; PYRIMIDINES; QUESTIONNAIRES; RISPERIDONE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 84871186758     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0109     Document Type: Article

References (59)

1. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL: Doubleblind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002. (Pubitemid 34832715)
2. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A: Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 48:1143-1154, 2009.
3. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E: Effects of short-and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545-550, 2007. (Pubitemid 46185331)
4. Bembo SA, Carlson HE: Gynecomastia: Its features, and when and how to treat it. Cleve Clin J Med 71:511-517, 2004. (Pubitemid 38832615)
5. Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV: An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 15:311-317, 2005. (Pubitemid 40734110)
6. Blaicher W, Imhof MH, Gruber DM, Schneeberger C, Sator MO, Huber JC: Endocrinological disorders. Focusing on melatonin's interactions. Gynecol Obstet Invest 48:179-182, 1999. (Pubitemid 29488321)
7. Bobes J, Garc APMP, Rejas J, Hernandez G, Garcia-Garcia M, Rico-Villademoros F: Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther 29:125-147, 2003. (Pubitemid 36278732)
8. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA: A cross-sectional evaluation of the effect of risperidone and selective serotonine reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 1:338-347, 2010.
9. Chan NP, Sung RY, Kong AP, Goggins WB, So HK, Nelson EA: Reliability of pubertal self-assessment in Hong Kong Chinese children. J Paediatr Child Health 44:353-358, 2008. (Pubitemid 351677487)
10. Citrome L: Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 22:90-97, 2008.
11. Coker F, Taylor D: Antidepressant-induced hyperprolactinaemia. CNS Drugs 24:563-574, 2010.
12. Correll CU: Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69:26-36, 2008a.
13. Correll CU: Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 20:195-201, 2008b. (Pubitemid 351489515)
14. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006. (Pubitemid 43932904)
15. Correll CU, Penzer JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK: Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am 15:177-206, 2006. (Pubitemid 41735243)
16. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S: Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64-72, 2005. (Pubitemid 40019201)
17. Cutler AJ: Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28:69-82, 2003. (Pubitemid 36015662)
18. Duke PM, Litt IF, Gross RT: Adolescents'self-assesment of sexual maturation. Pediatrics 66:918-920, 1980.
19. Emlinger MW, Kühnel W, Ranke MB: Reference ranges for serum concentrations of Lutotropin (LH), Follitropin (FSH), Estradiol (E2), Prolactin, Progesterone, Sex Hormone Binding Globuline (SHBG), Dehydroepiandrosterone sulfate (DHEAS), Cortisol and Ferritin in neonates, children and young adults. Clin Chem Lab Med 40:1151-1160, 2002. (Pubitemid 36024451)
20. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 47:316-323, 2000a. (Pubitemid 30127036)
21. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP: Body index measurements in 1996-7 compared with 1980. Arch Dis Child 82:107-112, 2000b. (Pubitemid 30305703)
22. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161: 677-684, 2004. (Pubitemid 38445512)
23. Graham SM, Howgate D, Anderson W, Howes C, Heliotis M, Mantalaris A, Tsiridis E, Tsapakis E: Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf 10:575-602, 2011.
24. Greenaway M, Elbe D: Focus on aripiprazole: A review of its use in child and adolescent psychiatry. J Can Acad Child Psychiatry 18:250-260, 2009.
25. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:2291-2314, 2004. (Pubitemid 39388605)
26. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28:53-67, 2003. (Pubitemid 36015661)
27. Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE: The role of tamoxifen in the management of gynaecomastia. Breast 15:276-280, 2006.
28. Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T, CAMESA Guideline Group: The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline Project: Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 20:234-241, 2011.
29. Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D: A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 32:315-326, 2006. (Pubitemid 43995227)
30. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ: What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 28:109-123, 2003. (Pubitemid 36335820)
31. Knegtering R, Baselmans P: Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162:1010-1012, 2005. (Pubitemid 40676220)
32. Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H: A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24:56-61, 2004. (Pubitemid 38139316)
33. Leone M, Comtois AS: Validity and reliability of self-assessment of sexual maturity in elite adolescent athletes. J Sports Med Phys Fitness 47:361-365, 2007.
34. McDougle CJ, Stigler KA, Erickson CA, Posey DJ: Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 69:15-20, 2008.
35. McKenna T: Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol 71:466-469, 2009.
36. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA: Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273-288, 2011.
37. Migliardi G, Spina E, D'Arrigo C, Gagliano A, Germanò E, Siracusano R, Diaz FJ, de Leon J: Short-and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry 33:1496-1501, 2009.
38. Molitch ME: Medication-induced hyperprolactinemia. Mayo Clin Proc 80:1050-1057, 2005. (Pubitemid 41099391)
39. Pollock A, McLaren EH: Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol 49:513-516, 1998. (Pubitemid 28475345)
40. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. New Engl J Med. 347:314-321, 2002.
41. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M: Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16:260-272, 2006. (Pubitemid 43902423)
42. Roke Y, Van Harten PN, Boot AM, Buitelaar JK: Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19:403-414, 2009.
43. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004. (Pubitemid 39473121)
44. Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P: Hyperprolactinemia: Different clinical expression in childhood. Horm Res Paediatr 73:187-192, 2010.
45. Schall JI, Semeao EJ, Stallings VA, Zemel BS: Self-assessment of sexual maturity status in children with Crohn's disease. J Pediatr 141:223-229, 2002.
46. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004. (Pubitemid 38068023)
47. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002. (Pubitemid 38338050)
48. Staller J: The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 16:317-326, 2006. (Pubitemid 43902428)
49. Stephen MD, Bryant WP, Wilson DP: Self-assessment of sexual maturation in children and adolescents with diabetes mellitus. Endocr Pract 14:840-845, 2008.
50. Stevens JR, Kymissis PI, Baker AJ: Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 15:893-900, 2005. (Pubitemid 43042980)
51. Stigler KA, Diener JT, KohnAE, Li L, Erickson CA, Posey DJ, McDougle CJ: Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: A 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19:265-274, 2009.
52. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: A pharmacovigilance study. Pharmacotherapy 26:748-758, 2006. (Pubitemid 43807626)
53. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110: e34, 2002.
54. Turrone P, Kapur S, Seeman MV, Flint AJ: Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159:133-135, 2002.
55. Verhelst J, Abs R: Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2:23-32, 2003. (Pubitemid 37051600)
56. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C: Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 19:629-635, 2009.
57. Wacharasindhu S, Pri-Ngam P, Kongchonrak T: Self-assessment of sexual maturation in Thai children by Tanner photograph. J Med Assoc Thai, 85:308-319, 2002.
58. Wink LK, Erickson CA, McDougle CJ: Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol 12:529-538, 2010.
59. Wolters HA, Knegtering H, Wiersma D, van den Bosch RJ: The spectrum of subjective effects of antipsychotic medication. Acta Neuropsychiatr 15:274-279, 2003. (Pubitemid 37267537)